Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

RPEP-009642004RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Published In:
Diabetic medicine : a journal of the British Diabetic Association, 21(11), 1204-12 (2004)
Database ID:
RPEP-00964

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-00964·https://rethinkpeptides.com/research/RPEP-00964

APA

Ratner, R E; Dickey, R; Fineman, M; Maggs, D G; Shen, L; Strobel, S A; Weyer, C; Kolterman, O G. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.. Diabetic medicine : a journal of the British Diabetic Association, 21(11), 1204-12.

MLA

Ratner, R E, et al. "Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.." Diabetic medicine : a journal of the British Diabetic Association, 2004.

RethinkPeptides

RethinkPeptides Research Database. "Amylin replacement with pramlintide as an adjunct to insulin..." RPEP-00964. Retrieved from https://rethinkpeptides.com/research/ratner-2004-amylin-replacement-with-pramlintide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.